Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 4067 results found since Jan 2013.

Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients
CONCLUSIONS: Statins appear to be generally well-tolerated in kidney transplant recipients. However, statin use might be associated with slightly higher risk of post-transplant diabetes mellitus, cataract, and rhabdomyolysis.PMID:36800538 | DOI:10.2215/CJN.0000000000000124
Source: Clinical Journal of the American Society of Nephrology : CJASN - February 17, 2023 Category: Urology & Nephrology Authors: Sunjae Bae JiYoon B Ahn Kmd Corey Joseph Ryan Whisler Mark A Schnitzler Krista L Lentine Bernard S Kadosh Dorry L Segev Mara A McAdams-DeMarco Source Type: research

Biden ’ s Physical Says He ’ s ‘ Healthy ’ and ‘ Vigorous, ’ But ‘ Gait Remains Stiff ’
President Biden, who turned 80 in November, was examined by doctors at Walter Reed National Medical Center in Maryland on Thursday. It was his first check up in over a year. Biden, the oldest President in US history, is widely expected to announce in the coming months that he is running for re-election. What were the results? His physician gave him a clean bill of health, but noted Biden continues to have stiffness in his walk from a combination of arthritis in his back, neuropathy in his feet and the long-term effects of breaking his foot in November 2020 while playing with his former dog Major. Doctors conducted a routin...
Source: TIME: Health - February 16, 2023 Category: Consumer Health News Authors: Brian Bennett Tags: Uncategorized Joe Biden Longevity White House Source Type: news

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017
Conclusions Statin use remains suboptimal for the secondary ASCVD prevention, particularly in women and older patients, and following ischaemic stroke and PAD hospitalisations. Improving this would offer substantial benefits to population health at low cost.
Source: Heart - February 14, 2023 Category: Cardiology Authors: Thalmann, I., Preiss, D., Schlackow, I., Gray, A., Mihaylova, B. Tags: Open access Healthcare delivery, economics and global health Source Type: research

Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial
AbstractPurpose of ReviewThe Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) demonstrated the clinical benefit of the combination of ezetimibe-simvastatin compared to placebo-simvastatin following acute coronary syndrome (ACS). This review highlights key findings from this study with particular attention to the practice-changing impact on guidelines for low-density lipoprotein cholesterol (LDL-C) reduction after ACS, especially among high-risk populations.Recent FindingsConsistent reductions in LDL-C have been reported with newer lipid-lowering therapies (proprotein convertase subtilisin/k...
Source: Current Atherosclerosis Reports - February 10, 2023 Category: Cardiology Source Type: research

A multicenter, prospective, randomized controlled trial of intracranial hemorrhage risk of intensive statin therapy in patients with acute ischemic stroke combined with cerebral microbleeds (CHRISTMAS): Study protocol
This study will shed light on new clinical decisions regarding the long-term serum lipid management in these patients with dilemma in clinical practice.Clinical trial registrationClinicaltrials.gov, identifier: NCT05589454.
Source: Frontiers in Neurology - February 9, 2023 Category: Neurology Source Type: research

Novel biomarkers and emerging tools to identify causal molecular pathways in hypertension and associated cardiovascular diseases
Kardiol Pol. 2023 Feb 5. doi: 10.33963/KP.a2023.0037. Online ahead of print.ABSTRACTHypertension (HT) is a modifiable risk factor for life-threatening cardiovascular diseases (CVDs) including coronary artery disease, heart failure or stroke. Despite significant progress in understanding of the pathophysiological mechanisms of the disease, the molecular pathways targeted by HT treatment still remain largely unchanged. This warrants the necessity for searching novel biomarkers, which are causally related to persistent high blood pressure (BP) and may be pharmacologically targeted. Data from large-scale biobanks, containing h...
Source: Polish Heart Journal - February 5, 2023 Category: Cardiology Authors: Ewelina J ózefczuk Tomasz J Guzik Mateusz Siedlinski Source Type: research

Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial
Conclusions. In REWIND, most women met clinically relevant treatment targets, but in lower proportions than men. Women had a lower risk for all cardiovascular outcomes except stroke. Clinical trials.gov registration number: NCT01394952.PMID:36723445 | DOI:10.1080/14017431.2023.2166101
Source: Scandinavian Cardiovascular Journal - February 1, 2023 Category: Cardiology Authors: Giulia Ferrannini Juan M Maldonado Sohini Raha Purnima Rao-Melacini Rutaba Khatun Charles Atisso Linda Shurzinske Hertzel C Gerstein Lars Ryd én M Angelyn Bethel Source Type: research